spironolactone has been researched along with acetaminophen in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (50.00) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Barecki, M; Casciano, CN; Clement, RP; Johnson, WW; Lew, K; Wang, E | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Nuss, GW; Risley, EA; Van Arman, CG | 1 |
| Catania, VA; Ikushiro, S; Luquita, MG; Mottino, AD; Ruiz, ML; Villanueva, SS | 1 |
| Autret-Leca, E | 1 |
| Liu, X; Wang, Q; Xu, R; Yang, J; Zang, M; Zhang, J | 1 |
1 review(s) available for spironolactone and acetaminophen
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
13 other study(ies) available for spironolactone and acetaminophen
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4.
Topics: 3T3 Cells; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Cell Survival; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Enzyme Inhibitors; Flow Cytometry; Humans; Mice; Microsomes, Liver; Mixed Function Oxygenases; Molecular Structure; Substrate Specificity | 2001 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Interactions of aspirin, indomethacin and other drugs in adjuvant-induced arthritis in the rat.
Topics: Acetaminophen; Animals; Anti-Inflammatory Agents; Arthritis; Aspirin; Body Weight; Chlorpromazine; Cyclophosphamide; Dexamethasone; Dose-Response Relationship, Drug; Drug Interactions; Hydrocortisone; Indomethacin; Male; Mycobacterium; Phenytoin; Prednisolone; Rats; Salicylates; Spironolactone; Time Factors | 1973 |
Beneficial effect of spironolactone administration on ethynylestradiol-induced cholestasis in the rat: involvement of up-regulation of multidrug resistance-associated protein 2.
Topics: Acetaminophen; Animals; Anion Transport Proteins; Antiporters; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile; Blotting, Western; Cholestasis, Intrahepatic; Ethinyl Estradiol; Gene Expression; Glucuronosyltransferase; Glutathione; Liver; Male; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organ Size; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; SLC4A Proteins; Spironolactone; Up-Regulation | 2007 |
[Drugs news].
Topics: Acetaminophen; Acupuncture; Asthma; Child; Glucocorticoids; Hemorrhage; Humans; Placebo Effect; Respiratory Distress Syndrome; Spironolactone | 2009 |
Changes in pharmacokinetic profiles of acetaminophen and its glucuronide after pretreatment with combinations of N-acetylcysteine and either glycyrrhizin, silibinin or spironolactone in rat.
Topics: Acetaminophen; Acetylcysteine; Animals; Glycyrrhizic Acid; Hepatobiliary Elimination; Injections, Intraperitoneal; Liver; Male; Rats, Sprague-Dawley; Silybin; Silymarin; Spironolactone; Time Factors | 2014 |